EPRX

EupraxiaD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$11.00

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$6.50

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$3.40

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-04

AI commentary

The packet contains no usable recent-news aggregate, social coverage, options skew, short-interest, or employee-sentiment data; zero values above indicate unavailable evidence rather than neutral readings. The deterministic prior is neutral-to-negative, with expected returns of -0.49% over 5 days, -1.41% over 20 days, -2.26% over 60 days, and -2.96% over 120 days, alongside very high uncertainty. Treat EPRX as a low-conviction clinical catalyst watch; no trusted post-release market reaction or analyst revision signal was available.

RankAlpha Sentiment Codex - 2026-08-04

Open full AI memo

Evidence flagged

small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-11-02eventRESOLVE Phase 2b topline data expected in Q4 2026High impact

The company states that its randomized, placebo-controlled Phase 2b RESOLVE study is recruiting 120mg and 160mg doses, with topline data expected in Q4 2026. Earlier open-label findings are supportive but small-sample and require controlled confirmation. [#IR-2026-05-05]

2026-11-02eventAdditional RESOLVE open-label dataHigh impact

Further data from the open-label Phase 1b/2a portion was expected in the coming months. The latest company-reported EREFS data showed stronger responses with 20 injections, but the dataset remains early-stage and limited. [#IR-2026-05-05]

2027-08-04catalystFunding visibility through major clinical milestonesHigh impact

The company reported $58.5 million of cash, $80.4 million of short-term investments, and an expectation that existing resources plus potential warrant proceeds could fund operations into the second half of 2028. [#SEC-6K-2026-05-12]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-04 • Updated nightlySource: Internal modelMethodology